Fisher Asset Management LLC Buys 116,299 Shares of Danaher Co. (NYSE:DHR)

Fisher Asset Management LLC raised its stake in Danaher Co. (NYSE:DHR) by 2.6% during the third quarter, HoldingsChannel.com reports. The fund owned 4,552,640 shares of the conglomerate’s stock after purchasing an additional 116,299 shares during the quarter. Fisher Asset Management LLC’s holdings in Danaher were worth $1,265,725,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Danaher in the second quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher in the 2nd quarter worth approximately $25,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher during the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC bought a new position in shares of Danaher during the 3rd quarter valued at approximately $55,000. Finally, MFA Wealth Advisors LLC purchased a new position in shares of Danaher in the second quarter valued at $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Robert W. Baird decreased their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Raymond James decreased their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Monday, November 18th. Six research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Trading Up 0.3 %

DHR stock opened at $235.84 on Monday. Danaher Co. has a 12 month low of $215.68 and a 12 month high of $281.70. The firm’s 50-day moving average is $258.15 and its 200 day moving average is $260.03. The company has a market capitalization of $170.34 billion, a PE ratio of 45.01, a P/E/G ratio of 4.34 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company posted $2.02 earnings per share. On average, research analysts anticipate that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.